RESULTS	After 12 months , plaque volume in SVG had increased ( median [ interquartile range ] ) by 7.7 mm ( 3 ) ( -17.2 to 37.9 ) in the placebo group and decreased by 0.3 mm ( 3 ) ( -19.1 to 22.3 ) in the rosiglitazone group ( P = 0.22 ) .\